Roivant Sciences (NASDAQ:ROIV) Director Sells $9,958,276.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 375,784 shares of Roivant Sciences stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $26.50, for a total value of $9,958,276.00. Following the sale, the director directly owned 15,127,329 shares in the company, valued at approximately $400,874,218.50. The trade was a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Wednesday, February 11th, Daniel Allen Gold sold 425,000 shares of Roivant Sciences stock. The shares were sold at an average price of $26.67, for a total transaction of $11,334,750.00.
• On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The stock was sold at an average price of $23.07, for a total transaction of $17,933,049.24.
• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The stock was sold at an average price of $23.04, for a total value of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00.

Roivant Sciences Trading Down 1.1%

NASDAQ:ROIV traded down $0.30 on Friday, reaching $26.45. 4,357,971 shares of the stock traded hands, compared to its average volume of 6,771,100. The company has a market capitalization of $18.40 billion, a price-to-earnings ratio of -22.61 and a beta of 1.22. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $27.94. The company’s fifty day simple moving average is $22.71 and its 200 day simple moving average is $18.31.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ROIV. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 target price on shares of Roivant Sciences in a research report on Monday. Weiss Ratings lowered shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday. Guggenheim increased their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Leerink Partners raised their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.69.

Key Headlines Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
• Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
• Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
• Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near‑term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
• Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
• Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near‑term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently modified their holdings of ROIV. Penn Davis Mcfarland Inc. boosted its position in shares of Roivant Sciences by 10.1% during the third quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock worth $28,173,000 after acquiring an additional 170,456 shares during the last quarter. Valeo Financial Advisors LLC bought a new stake in Roivant Sciences in the 2nd quarter valued at $1,145,000. IFG Advisory LLC purchased a new stake in Roivant Sciences in the 2nd quarter worth $255,000. Y Intercept Hong Kong Ltd bought a new position in shares of Roivant Sciences during the 2nd quarter valued at about $3,064,000. Finally, Franklin Resources Inc. bought a new position in shares of Roivant Sciences during the 2nd quarter valued at about $997,000. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.